Swissmedic

Summary report on authorisation – Ojemda®

Marketing authorisation granted for Ojemda® (pharmaceutical product).

Low obligation Product class Pharmaceuticals Switzerland Pharmaceuticals

25.08.2026

Dates and deadlines

Applies from

2026-08-25

Read the official source ↗

Published by Swissmedic. HealthSignal links to the original document; the summary above is extracted from the source text.